Corcept Therapeutics Inc (CORT) is expected to grow earnings and revenues in the years ahead

At the time of writing, Corcept Therapeutics Inc [CORT] stock is trading at $71.24, down -0.85%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling.

From an analyst’s perspective:

Corcept Therapeutics Inc [NASDAQ: CORT] stock has seen the most recent analyst activity on November 06, 2023, when Truist upgraded its rating to a Buy and also boosted its price target to $38 from $29. Previously, SVB Securities started tracking the stock with Market Perform rating on April 11, 2023, and set its price target to $25. On April 04, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $27 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $22 on February 15, 2023. Truist downgraded its rating to a Hold but $30 remained the price target by the analyst firm on August 01, 2022. Jefferies upgraded its rating to Buy for this stock on July 27, 2022, and upped its price target to $35.

For the past year, the stock price of Corcept Therapeutics Inc fluctuated between $28.09 and $117.33. Currently, Wall Street analysts expect the stock to reach $140 within the next 12 months. Corcept Therapeutics Inc [NASDAQ: CORT] shares were valued at $71.24 at the most recent close of the market. An investor can expect a potential return of 96.52% based on the average CORT price forecast.

Analyzing the CORT fundamentals

According to Corcept Therapeutics Inc [NASDAQ:CORT], the company’s sales were 685.45M for trailing twelve months, which represents an 7.09% jump. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.16%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.19%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.2 and Total Capital is 0.16. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 70.31 points at the first support level, and at 69.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 72.65, and for the 2nd resistance point, it is at 74.06.

Ratios To Look Out For

It is important to note that Corcept Therapeutics Inc [NASDAQ:CORT] has a current ratio of 3.07. Further, the Quick Ratio stands at 2.96, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 11.02, the price to book ratio is 11.05 and price to earnings (TTM) ratio is 61.83.

Transactions by insiders

Recent insider trading involved Robb Gary Charles, Chief Business Officer, that happened on Jun 16 ’25 when 3185.0 shares were sold. Officer, Robb Gary Charles completed a deal on Jun 16 ’25 to buy 3185.0 shares. Meanwhile, Director Swisher Daniel N JR sold 2200.0 shares on Jun 10 ’25.

Related Posts

MZP News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.